Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
Healthcare
$4.34 -0.15%
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
52W Low $5.44High $9.42
Volume 0.47M
Average 0.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$1.01M
FY 2025 · Annual
Investing Cash Flow
-$474,000.00
FY 2025 · Annual
Financing Cash Flow
$24.38M
FY 2025 · Annual
+1059.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | 4.31M | (85.48M) | 17.9M | 9.88M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.48M |
| Deferred Income Tax | (3.89M) | (838K) | (1.16M) | (1M) | (1.11M) |
| Stock-Based Compensation | 3.41M | 13.37M | 7.28M | 831K | 7.16M |
| Change in Working Capital | 483K | (7.8M) | 7.46M | (15.69M) | (15.55M) |
| Accounts Receivables | 1.5M | (7.92M) | 1.3M | (9.29M) | (11.95M) |
| Inventory | 3.88M | (879K) | 1.75M | (2.14M) | (3.63M) |
| Accounts Payables | 500K | (112K) | 192K | (245K) | 13K |
| Other Working Capital | (5.39M) | 1.11M | 4.22M | (4.02M) | 17K |
| Other Non-Cash Items | 3.89M | 503K | 96.68M | (7.27M) | (1.85M) |
| Operating Cash Flow | (83.76M) | 10.68M | 25.89M | (3.64M) | 1.01M |
| Capital Expenditures | (839K) | (5M) | (8.59M) | (3.13M) | (1.19M) |
| Acquisitions (Net) | 0 | (1.33M) | 4.02M | (1.69M) | 30K |
| Purchases of Investments | 0 | (7.48M) | (15.74M) | (15.47M) | 0 |
| Sales of Investments | 49.03M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (13K) | 471K | (412K) | 686K |
| Investing Cash Flow | 48.19M | (13.81M) | (19.76M) | (19.88M) | (474K) |
| Debt Repayment | (6.7M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 49.55M | 0 | 0 | 773K | 25.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.7M | 0 | 0 | 1.33M | (1.49M) |
| Financing Cash Flow | 49.55M | 0 | 2.5M | 2.1M | 24.38M |
| Effect of Forex Changes | 0 | (1.89M) | (298K) | (273K) | 343K |
| Net Change in Cash | 13.99M | (5.03M) | 8.33M | (21.7M) | 25.26M |
| Free Cash Flow | (84.59M) | 5.68M | 17.31M | (6.77M) | (180K) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$9.9M
+ D&A$2.5M
+ Stock-Based Comp$7.2M
- Deferred Tax-$1.1M
- Working Capital-$15.6M
- Other Non-Cash-$1.8M
= Operating Cash Flow$1.0M
- Capex-$1.2M
= Free Cash Flow-$180.0K
Analysis
FY2025 free cash flow is -$180.0K. FCF conversion is -1.8% of net income. Operating cash flow was $1.0M, with capex of -$1.2M. The largest bridge item is Working Capital at -$15.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| 8-K | Current report | Sep 1, 2026 | |
| S-8 | S-8 filing | Aug 27, 2026 |
Does GYRE generate free cash flow?
Gyre Therapeutics, Inc. (GYRE) generated -$180,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does GYRE produce?
Operating cash flow was $1.01M, before capital expenditures of $1.19M.
Continue the stock analysis
Jump to another research area for this company.